The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The use of MRD in mantle cell lymphoma: a valuable prognostic tool
In this video, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, comments on the use of measurable residual disease (MRD) in mantle cell lymphoma (MCL), highlighting its value as a prognostic marker after CAR T-cell therapy and its potential use as a surrogate endpoint. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think MRD is a really important tool and endpoint potentially in mantle cell lymphoma, and there’s a couple different ways that we might think about it. So I think first and foremost, right now, it tends to be a prognostic marker. One area in which it’s quite useful is post-CAR T-cell therapy. So when we look at patients who have really very durable outcomes after CAR T-cells for mantle cell, those patients who are undetectable MRD do seem to have the best durability of outcomes...
So I think MRD is a really important tool and endpoint potentially in mantle cell lymphoma, and there’s a couple different ways that we might think about it. So I think first and foremost, right now, it tends to be a prognostic marker. One area in which it’s quite useful is post-CAR T-cell therapy. So when we look at patients who have really very durable outcomes after CAR T-cells for mantle cell, those patients who are undetectable MRD do seem to have the best durability of outcomes. So that might be one area that sometimes I will use it in the clinic now. I think the shift is really moving towards use in upfront therapy. So we’re seeing the shift in mantle cell lymphoma away from chemotherapy towards more combinations of novel or targeted therapies. And there, I think MRD will be really important to help us as a surrogate endpoint or a proxy for long-term outcomes and so that’s where we’re starting to see more data generated.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
